A study published in Circulation found that patients who took both aspirin and rivaroxaban twice a day had a consistent and similar relative risk reduction for cardiovascular death, myocardial infarction or stroke in patients with and without diabetes, compared with those who took placebo and aspirin. Based on data from 18,278 patients, the findings also revealed that those with diabetes had greater absolute risk reductions with rivaroxaban for the primary efficacy endpoint at three years and for all-cause mortality, compared with those without the disease.
Rivaroxaban, aspirin combo lower CVD risk in diabetes
Sign up for SNMMI SmartBrief
Nuclear medicine and molecular imaging news
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.